AstraZeneca Aims To Shake Plavix Off The Throne With Launch Of Brilinta In China
This article was originally published in PharmAsia News
AstraZeneca launches Brilinta in China, aiming to grow its share of a $1.5 billion antithrombotic market at the expense of Sanofi’s Plavix.
You may also be interested in...
A study published in the New England Journal of Medicine showed Effient was not superior to Plavix in treating patients who had not undergone revascularization.
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.